Find a Clinical Trial

Showing 1 - 10 of 26 Trials

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06608927

Population:

Adult

Phase:

III

The purpose of this research is to determine the safety and efficacy of investigational study drug quemliclustat (also known as AB680) in combination with chemotherapy gemcitabine and nab-paclitaxel (Gem-NP), compared to a placebo (saline solution not containing treatment drug) in combination with chemotherapy gemcitabine and nab-paclitaxel at treating participants with the type of cancer you have. Quemliclustat has not been approved by the Food and Drug Administration (FDA). Gemcitabine and nab-paclitaxel (Gem-NP) is FDA approved but not in combination with quemliclustat. This is a double-...
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05968326

Population:

Adult

Phase:

II

The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus atezolizumab and mFOLFIRINOX compared with mFOLFIRINOX (standard of care chemotherapy) alone on patients with resected pancreatic ductal adenocarcinoma (PDAC). In this study, the participant will get either the combination of autogene cevumeran plus atezolizumab and mFOLFIRINOX or mFOLFIRINOX alone. Autogene cevumeran is a personalized drug product that will be made specifically for the participant and is designed to activate and train your immune system to find and kill cancer cells. Autogene...
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating neoadjuvant therapy targeting the Adenosine immunosuppressive pathway in combination with Immune checkpoint blockade and Radiation Therapy in Patients with advanced PANCreatic Ductal

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06048484

Population:

Adult

Phase:

II

The main goal of this study is to find out if treatment with zimberelimab and stereotactic body radiation therapy alone or in combination with quemliclustat, with or without etrumadenant, given before surgery is safe and if it can further increase the immune response against the tumor. Are you Eligible? (Inclusion Criteria) You must have been diagnosed with advanced pancreatic adenocarcinoma. -You must be comfortable receiving study drug through a vein in your arm (intravenously). -You must be willing to undergo surgery.
A Phase I/IIa Randomized Clinical trial to Evaluate the Efficacy of EGFR-targeted, PNU159682-packaged Nanocells and Glycolipid-Packaged Nanocells in combination withGemcitabine and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT07049055

Population:

Adult

Phase:

I/II

The purpose of this study is to test a new experimental treatment for people with pancreatic cancer that has spread (metastatic PDAC). The experimental treatment being evaluated is called EGFR-targeted EnGeneIC Dream Vector™ (EDV™), carrying a drug called PNU-159682, or E-EDV-D682, referred to as the “study drug.” The study drug is investigational and has not been approved by the United States Food and Drug Administration (FDA). The study drug is a type of chemotherapy packaged inside a delivery vehicle (manufactured from a non–disease- causing salmonella...
Chemo4METPANC - A Phase 2 study with combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (Motixafortide), and immune checkpoint blockade (Cemiplimab) in METastatic treatment naïve PANCreas

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT04543071

Population:

Adult

Phase:

II

You are being invited to take part in this research study because you have been diagnosed with pancreas cancer that has spread to other parts of the body. The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing tumor size and prolonging life in patients with advanced pancreas cancer. The treatment consists of both immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel). Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA...
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized,2-Arm Study of Adjuvant Daraxonrasib versus Standard of CareObservation Following Completion of Neoadjuvant and/orAdjuvant Chemotherapy in Patients with Resected PancreaticDuctal Adenocarcinoma

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07252232

Population:

Adult

Phase:

III

The purpose of this study is to test an experimental drug called Daraxonrasib (RMC-6236) compared to standard of care observation after finishinged chemotherapy given either before surgery to shrink the tumor (neoadjuvant chemotherapy) or after surgery to kill remaining cancer cells in patients with resected PDAC. Daraxonsrasib (RMC-6236) is not approved by the United States Food and Drug Administration (FDA). People who usually have this type of cancer typically receive surgery followed by chemotherapy, and then are monitored without additional treatment. This study is different because it...
A Platform Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06445062

Population:

Adult

Phase:

I/II

The purpose of this study is to test the safety of an experimental drug called RMC-6236 in combination with several chemotherapy medicines in patients with gastrointestinal cancers. The study will test the safety of RMC-6236 at different doses in combination with a fixed, standard dose of combination anti-cancer therapy, and how your body processes this combination. RMC-6236 is an investigational (experimental) drug, which means that it has not been approved by the United States (US) Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years old or older -...
A Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy ofONC-783 in Advanced Solid Tumors

Principal Investigator:

Aiwu R He, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07408258

Population:

Adult

Phase:

I

This research study is a first-in-human Phase 1 study. The study tests the effects of study drug, ONC-783, in the treatment of advanced or metastatic colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer. The most important measurement for the study is to see whether ONC-783 is safe and tolerable, how it is processed in the blood/body and whether it could slow down tumor growth. ONC-783 is an investigational drug being developed as an anti-tumor treatment. ONC-783 is a bispecific antibody drug, which means it may bring immune cells (that protect the body against diseases) and...
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 asMonotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT07277413

Phase:

I

The purpose of this study is to determine the ideal dose of the study drugs, IDE892 by itself and IDE892 in combination with IDE397, and to find out what effect, good and/or bad, these study drugs may have on your cancer. This will be first human study for IDE892. Both IDE892 and IDE397 has not been approved by the United States (US) Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must be willing and able to provide blood/tumor tissue samples for biomarker testing - Must be able to swallow and retain the study drug
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06561685

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans. Are you Eligible...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages